Molecular Detection of Mycobacterium tuberculosis (MTB) and Rifampicin Resistant Strain among Subjects Accessing Health Care at Federal Medical Centre, Yenegoa, Bayelsa State; Nigeria

Abstract

Background: An increasing global incidence of Mycobacterium Tuberculosis (MTB), and emergence of drug resistant strains of MTB, have critically promoted the urgent need to explore better effective methods that can rapidly detect MTB, and identify drug-resistant cases as recommended by World Health Organization report of 2008. Globally, multi-drug-resistant strains of MTB are increasingly becoming a huge public health issue, which has adversely affected the health care delivery of patients, especially in developing communities with limited functioning health care facility. Nonetheless, the aim and focus of the study is to evaluate the trend of rifampicin resistance strains of MTB among patients accessing care at the Federal Medical Centre Yenegoa, Bayalsa State.

Trends of Mycobacterium Tuberculosis and rifampicin resistance in Adigrat General Hospital, Eastern Zone of Tigrai, North Ethiopia

“…In this study, Mycobacterium tuberculosis was prevalent in all ages, but have seriously hit the age group of 30-44 years with 26.0% and of whom 34/420 (8.1%) were rifampicin resistant. The positivity nding was in line with studies conducted in Gondar (29.8%) [14], different studies in Ethiopia [21][22][23]35], WHO reports 2017 [2] and Agaro Teaching Health Center in southwestern Ethiopia [36].However, contrary ndings with several studies in a different part of Nigeria and Zambia [18,24,33] which had lower prevalence, but higher than a study conducted in eastern Uttar Pradesh (40%) [19].…”

“…However, it was lower compared to reports in Jigjiga (65.5%) [17], Kenya (32.25%) [18], in eastern Uttar Pradesh (32.9%) [19] and Congo (79.1%) [47].The main difference in these latter ndings may show our inclusion of all forms of presumptive tuberculosis while other studies included identi ed cases of Mycobacterium tuberculosis. In contrast, our nding was higher when compared with studies conducted in Metema and Armacho (5.7%) [6], Felege Hiwot Referral Hospital, and Debre Tabor Hospital (14.6%) [20], in three referral hospitals and the regional laboratory in Addis Ababa (15.11%) [48], other parts of Ethiopia (4.7%-10.8%) [21][22][23], Nigeria (10.3%) [24] and India (2.31%) [25].The variations might be due to the difference in study design, type and number of participants, and environmental conditions.…”

“…According to our study, we found 132 (9.1%) of rifampicin-resistant cases among con rmed TB cases. This result is comparable with studies conducted in Debre Markos Referral Hospital (10.3%) [13], Felege Hiwot Referral Hospital and Debre Tabor Hospital (9.3%) [20], Addis Ababa (9.9 %) [48] and India (10.5%) [38].Our nds are higher than studies conducted on northwest, east and south parts of Ethiopia (2.9%-5.7%) [6,19,31-32,39,42,46 and 48], Nigeria (2.9%) [24] and Zambia (5.9%) [33].The possible explanation for these variations could be related to our retrospective approach spanning four years, or differences in study designs .However, our incidence was lower than for studies conducted in Gondar 15.8% [14],other parts of Ethiopia (11.5-39.4) [39-40and 51],Congo (42.2%) [47] and China (17.6-26.3%) [43 and 50].…”

Trends of Mycobacterium Tuberculosis and Rifampicin resistance in Adigrat General Hospital, Eastern zone, Tigray Region, Northern Ethiopia

“…the main difference in these latter findings may show our inclusion of all forms of presumptive tuberculosis while other studies included identified cases of Mycobacterium tuberculosis. In contrast, our finding was higher when compared with studies conducted in Metema and Armacho (5.7%) [6], Felege Hiwot Referral Hospital, and Debre Tabor Hospital (14.6%) [20], in three referral hospitals and the regional laboratory in Addis Ababa (15.11%) [48], other parts of Ethiopia (4.7%-10.8%) [21][22][23], Nigeria (10.3%) [24] and India (2.31%) [25].The variations might be due to the difference in study design, type & number of participants, and environmental conditions.…”

“…The positivity finding was in line with studies conducted in Gonder (29.8%) [14], different studies in Ethiopia [21][22][23]35], WHO reports 2017 [2] & Agaro Teaching Health Center in southwestern Ethiopia [36]. There are however contrary findings with several studies in a different part of Nigeria and Zambia [18,24,33] which had lower prevalence, but higher than a study conducted in eastern Uttar Pradesh (40%) [19].…”